EYEVENSYS
Eyevensys is a address critical unmet needs in ophthalmology by providing a much better way of delivering ophthalmic drugs that overcomes the limitations of current options, such as intravitreal injections, surgery, intravitreal implants and biodegradable formulations. All of these current options have their drawbacks, given they are invasive procedures. Eyevensys’ goal is not only to improve short and long term therapeutic outcomes, but also to enhance compliance, improve ocular bioavailability and tolerability. They plan to build a high value product pipeline by enabling sustained production of therapeutic proteins in the eye that will deliver improved clinical outcomes while reducing the burden of frequent intravitreal or systemic injections and other invasive procedures.
EYEVENSYS
Social Links:
Industry:
Biotechnology Medical Device Therapeutics
Founded:
2008-01-01
Address:
Paris, Ile-de-France, France
Country:
France
Website Url:
http://www.eyevensys.com
Total Employee:
11+
Status:
Active
Contact:
+33 (0)1 84 79 10 60
Email Addresses:
[email protected]
Total Funding:
52.12 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress Font Awesome
Current Advisors List
Current Employees Featured
Founder
Investors List
Korea Investment Partners
Korea Investment Partners investment in Series B - Eyevensys
Karista
Karista investment in Series B - Eyevensys
Quark Venture
Quark Venture investment in Series B - Eyevensys
Global health sciences venture fund
Global health sciences venture fund investment in Series B - Eyevensys
Bpifrance
Bpifrance investment in Series B - Eyevensys
Inserm Transfert Initiative
Inserm Transfert Initiative investment in Series B - Eyevensys
Pureos Bioventures
Pureos Bioventures investment in Series B - Eyevensys
Pontifax
Pontifax investment in Series B - Eyevensys
Boehringer Ingelheim Venture Fund
Boehringer Ingelheim Venture Fund investment in Series B - Eyevensys
Pontifax
Pontifax investment in Series A - Eyevensys
Key Employee Changes
| Date | New article |
|---|---|
| 2020-03-10 | Eyevensys Announces Executive Leadership Team Expansion |
Official Site Inspections
http://www.eyevensys.com Semrush global rank: 5.79 M Semrush visits lastest month: 1.44 K
- Host name: redirect.ovh.net
- IP address: 213.186.33.5
- Location: France
- Latitude: 48.8582
- Longitude: 2.3387
- Timezone: Europe/Paris
More informations about "Eyevensys"
Eyevensys - Crunchbase Company Profile & Funding
Eyevensys is a address critical unmet needs in ophthalmology by providing a much better way of delivering ophthalmic drugs that overcomes the limitations of current options, such as intravitreal injections, surgery, intravitreal implants …See details»
www.eyevensys.com Game changer for ophthalmic diseases - Nature
Eyevensys’ lead candidate, EYS606, is a plasmid ... organization has the financial backing of the Boehringer Ingelheim Venture Fund and others such as BPI France-Innobio, Inserm Transfert ...See details»
Eyevensys Company Profile - Office Locations, Competitors ... - Craft
Eyevensys is a biotechnology company developing its innovative EyeCET platform to enable the sustained intraocular production of therapeutic proteins to treat a broad range of ophthalmic …See details»
Eyevensys - VentureRadar
"Eyevensys is a privately held, clinical-stage biotechnology company. Our first-in-class, non-viral vector gene therapy, sustained drug delivery system offers a new approach to treating major …See details»
Eyevensys' CEO: Why a US Presence Helps European Biotechs …
Aug 24, 2020 Eyevensys started in Paris in 2008 based on the research of Francine Behar-Cohen, a professor at Paris Descartes University. While many gene therapy companies inject …See details»
Eyevensys raises $12M for its gene therapy ocular drug delivery ...
Aug 4, 2021 Eyevensys, a developer of gene therapies for ophthalmic diseases, announced today that it raised $12 million in a Series B plus funding round.. The funding, led by Korea …See details»
Eyevensys Raises $12M in a Series B Plus Funding Round
Aug 4, 2021 Eyevensys is advancing a dual gene plasmid, EYS809, expressing two therapeutic proteins, a potent VEGF inhibitor and an endogenous protein with anti-angiogenic and …See details»
Eyevensys : Receives FDA Orphan Drug Designation for EYS611 for ...
Oct 5, 2020 Eyevensys is also advancing a dual gene plasmid, EYS809, expressing two therapeutic proteins for wet AMD, diabetic macular edema, and central retinal vein occlusion, …See details»
Eyevensys to present at The Association for Research in Vision and ...
Apr 29, 2022 Eyevensys is advancing a dual gene plasmid, EYS809, expressing two therapeutic proteins, a potent VEGF inhibitor and an endogenous protein with anti-angiogenic and …See details»
Eyevensys Receives FDA Orphan Drug Designation for EYS611 for …
Oct 5, 2020 Eyevensys' lead product EYS606 is a potential new treatment for patients with chronic non-infectious uveitis (NIU). EYS606 combines Eyevensys' proprietary …See details»
Dallas News: Paris and Fort Worth-based biotech company …
ARVO 2023: Eyevensys announces positive preclinical data demonstrating efficacy of EYS809 over aflibercept for wet AMD; Eyevensys Recaps Highlights from Investigator Meeting and …See details»
Eyevensys' degenerative eye treatment receives orphan-drug tag …
Oct 5, 2020 Eyevensys S.A.S.'s therapy for a rare degenerative eye disease has received the orphan-drug designation by the U.S. Food and Drug Administration. The eye disease, retinitis …See details»
Eyevensys links with Phillips-Medisize, Minnetronix to produce its …
Sep 27, 2021 Eyevensys formed its two new partnerships shortly after raking in more than $40 million in a dual-tranche series B venture funding round. The round first closed at the …See details»
Eyevensys Announces Positive Preclinical Data Demonstrating …
Apr 24, 2023 Eyevensys is a privately held, clinical-stage biotechnology company developing its innovative technology to enable the sustained intraocular production of therapeutic proteins to …See details»
Eyevensys bags $12M to test non-viral gene therapy delivery tech
Aug 10, 2021 EYS809 is yet to reach the clinic but has become the focus of development at Eyevensys. Another gene therapy, EYS606, made it to phase 2 in non-infectious uveitis, but …See details»
Eyevensys Presents Initial Data from Phase I/II Trial of Innovative ...
Oct 11, 2019 Eyevensys is a private clinical stage biotechnology company developing its innovative technology to enable the sustained intraocular production of therapeutic proteins to …See details»
Game changer for ophthalmic diseases - Nature
Eyevensys is pioneering mini-invasive electroporation to express therapeutic proteins in situ to treat major ophthalmic diseases.See details»
Eyevensys Announces the First-in-Human Treatment with its ...
May 9, 2017 Eyevensys is a private clinical stage biotechnology company developing its innovative EyeCET platform to enable the sustained intraocular production of therapeutic …See details»
Eyevensys Recaps Highlights from Investigator Meeting and …
May 11, 2022 Eyevensys is a privately held, clinical-stage biotechnology company developing its innovative technology to enable the sustained intraocular production of therapeutic proteins to …See details»
Eyevensys Enters Collaboration with Phillips-Medisize and …
Sep 27, 2021 Eyevensys is a privately held, clinical-stage biotechnology company developing its innovative technology to enable the sustained intraocular production of therapeutic proteins to …See details»